Related Experiment Videos
AbobotulinumtoxinA: A 25-Year History.
Gary D Monheit1, Andy Pickett2,3
1Dermatologist, Departments of Dermatology and Ophthalmology, University of Alabama at Birmingham, Birmingham, AL, USA.
Aesthetic Surgery Journal
|April 8, 2017
Summary
Botulinum toxin type A (BoNT-A) revolutionized strabismus treatment. This review celebrates Dysport
Area of Science:
- Neurology
- Ophthalmology
- Pharmacology
Background:
- Botulinum toxin (BoNT) injections, pioneered by Alan Scott, offered a non-surgical alternative for strabismus.
- Early adoption by UK clinicians highlighted BoNT type A's therapeutic potential for various challenging conditions.
Purpose of the Study:
- To review the history of abobotulinumtoxinA (Dysport) on its 25th anniversary.
- To highlight the evolution of BoNT applications beyond initial therapeutic aims.
Main Methods:
- Historical review of Dysport's development and commercialization.
- Examination of the expansion of BoNT-A indications and market.
Main Results:
- Dysport, developed through UK collaboration, gained European approval for dystonias in 1990.
- Dysport now holds marketing authorizations in 75 countries.
- BoNT-A use has expanded significantly into aesthetic and emerging therapeutic areas.
Conclusions:
- Dysport's journey exemplifies the successful translation of scientific discovery into widespread clinical application.
- The growing market for BoNT products, including biosimilars and new formulations, indicates continued innovation.
- Ongoing research explores novel indications for BoNT-A, such as acne and psoriasis.